Overall, approximately 80% of lower-grade gliomas and secondary glioblastomas harbor an IDH1 or IDH2 mutation, thus supporting the inclusion of this class of mutations in mouse models of these glioma subtypes [155]. This evidence concerns the gene IDH2 and glioblastoma.